Skip to content
OpenCapital
Get started

Artiva Biotherapeutics, Inc. ARTV Cash And Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost Excluding Interest After Allowance For Credit Loss

Other financials

Income statement

See full
Revenue-—
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%—
Net margin-79.3%—

Returns & leverage

See full
Return on equity-67.9%—
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept artv:CashAndCashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCostExcludingInterestAfterAllowanceForCreditLoss.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss?
Artiva Biotherapeutics, Inc. (ARTV) reported cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss of $86.8M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss changed year-over-year?
Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss decreased by 47.7% year-over-year, from $165.96M to $86.8M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s cash and cash equivalents at carrying value and available for sale debt securities amortized cost excluding interest after allowance for credit loss has grown at a 18.6% compound annual growth rate (CAGR), from $76.66M to $107.91M.